Stocks to Watch: Rumble, Lexicon Pharmaceuticals

WSJ12/21 07:19

FDA Rejects Lexicon's Zynquista for Diabetes, Kidney Disease

Seeking Alpha12/21 06:30

Lexicon Fails to Secure FDA Approval for Zynquista -- Shares Fall After Hours

MT Newswires12/21 05:53

Lexicon Receives Complete Response Letter for Zynquista; Says This Expected Communication From The FDA Aligns With Previously Disclosed Strategic Decision To Discontinue Launch Preparations For Zynquista And Focus Solely On Its Clinical Development...

Benzinga12/21 05:34

Lexicon Announces Receipt of Complete Response Letter for Zynquista (Sotagliflozin)

GlobeNewswire12/21 05:30

Painful Week for Private Equity Firms Invested in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After 24% Drop, Institutions Also Suffered Losses

Simply Wall St12/20 02:15